Tratamento das micobacterioses não tuberculosas: revisão integrativa da literatura (2020–2026)

This integrative review examines recent evidence on the treatment of nontuberculous mycobacterial pulmonary disease, a condition characterized by prolonged treatment, significant toxicity, and modest outcomes. The study aimed to synthesize findings published between 2020 and 2026 regarding therapeutic regimens, tolerability, treatment adherence, clinical outcomes, and emerging therapies. The literature search was conducted in PubMed/MEDLINE, supplemented by manual searches and official documents, with study selection based on the PRISMA 2020 guidelines. Of the 144 records identified, 43 studies met the eligibility criteria, including clinical guidelines, clinical trials, meta-analyses, systematic reviews, and cohort studies. The combination of a macrolide, ethambutol, and a rifamycin remains the cornerstone of treatment for Mycobacterium avium complex disease, achieving treatment success in approximately two-thirds of patients. Intermittent regimens, two-drug regimens, and lower doses of ethambutol reduced toxicity while maintaining comparable efficacy in patients with the nodular-bronchiectatic form of the disease. Inhaled liposomal amikacin increased sustained culture conversion rates from 47.6% to 76.2% in newly diagnosed patients, whereas oral omadacycline demonstrated preliminary benefits against Mycobacterium abscessus. Adverse events occurred in 59% of treated patients and led to drug discontinuation in 15%, while early treatment interruption was associated with increased mortality. Completion of treatment in accordance with clinical guidelines was associated with a higher likelihood of cure and lower mortality. Evidence from Brazil remains scarce and is limited to hospital-based case series. In conclusion, treatment for nontuberculous mycobacterial pulmonary disease is advancing through the use of inhaled and repurposed drugs; however, successful management depends on species identification, drug susceptibility testing, and adherence support. These aspects need to be strengthened within the Brazilian Unified Health System (SUS), particularly in the Northern Region.

Authors

Publication Details

Journal
Revista fisio&terapia.
Published
2026-11-19
DOI
https://doi.org/10.69849/c962x425
Primary Topic
Mycobacterium research and diagnosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tratamento das micobacterioses não tuberculosas: revisão integrativa da literatura (2020–2026)

Luan Felipo Botelho Souza, Emilly Lourdes Boaria, Diego Santos Fulber, Júlia Ianes de Carvalho Neta
Revista fisio&terapia.
Mycobacterium research and diagnosis
article

Tratamento das micobacterioses não tuberculosas: revisão integrativa da literatura (2020–2026)

Luan Felipo Botelho Souza, Emilly Lourdes Boaria, Diego Santos Fulber, Júlia Ianes de Carvalho Neta
article en

Abstract

This integrative review examines recent evidence on the treatment of nontuberculous mycobacterial pulmonary disease, a condition characterized by prolonged treatment, significant toxicity, and modest outcomes. The study aimed to synthesize findings published between 2020 and 2026 regarding therapeutic regimens, tolerability, treatment adherence, clinical outcomes, and emerging therapies. The literature search was conducted in PubMed/MEDLINE, supplemented by manual searches and official documents, with study selection based on the PRISMA 2020 guidelines. Of the 144 records identified, 43 studies met the eligibility criteria, including clinical guidelines, clinical trials, meta-analyses, systematic reviews, and cohort studies. The combination of a macrolide, ethambutol, and a rifamycin remains the cornerstone of treatment for Mycobacterium avium complex disease, achieving treatment success in approximately two-thirds of patients. Intermittent regimens, two-drug regimens, and lower doses of ethambutol reduced toxicity while maintaining comparable efficacy in patients with the nodular-bronchiectatic form of the disease. Inhaled liposomal amikacin increased sustained culture conversion rates from 47.6% to 76.2% in newly diagnosed patients, whereas oral omadacycline demonstrated preliminary benefits against Mycobacterium abscessus. Adverse events occurred in 59% of treated patients and led to drug discontinuation in 15%, while early treatment interruption was associated with increased mortality. Completion of treatment in accordance with clinical guidelines was associated with a higher likelihood of cure and lower mortality. Evidence from Brazil remains scarce and is limited to hospital-based case series. In conclusion, treatment for nontuberculous mycobacterial pulmonary disease is advancing through the use of inhaled and repurposed drugs; however, successful management depends on species identification, drug susceptibility testing, and adherence support. These aspects need to be strengthened within the Brazilian Unified Health System (SUS), particularly in the Northern Region.

Revista fisio&terapia.Vol. 30(164)
Mycobacterium research and diagnosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon